<DOC>
	<DOCNO>NCT00973882</DOCNO>
	<brief_summary>The aim study assess efficacy toxicity chemotherapy regimen combine carboplatin etoposide patient metastatic hormone-resistant prostate cancer neuro-endocrine differentiation . Eligible patient treat combination carboplatin AUC4 day 1 etoposide 100 mg/m2 day 1 , day 2 day 3 repeat every 3 week maximum 6 cycle . Efficacy endpoint include Prostate Specific Antigen ( PSA ) neuro-endocrine marker response ( defined 50 % great decrease baseline serum value ) , objective response rate ( accord RECIST criterion ) , toxicity .</brief_summary>
	<brief_title>Carboplatin-Etoposide Combination Hormone-Resistant Prostate Cancers</brief_title>
	<detailed_description>Neuro-endocrine differentiation observe evolution hormone-resistant prostate cancer . The aim study assess efficacy toxicity chemotherapy regimen combine carboplatin etoposide patient metastatic hormone-resistant prostate cancer neuro-endocrine differentiation . To eligible , patient must either circulate neuro-endocrine marker ( Chromogranin A : CgA , Neuron Specific Enolase : NSE ) and/or visceral metastasis . Eligible patient treat combination carboplatin AUC4 administer day 1 etoposide 100 mg/m2 give day 1 , day 2 day 3 repeat every 3 week maximum 6 cycle . The primary objective study assess objective response carboplatin - etoposide combination ( accord RECIST criterion lesion define 50 % great decrease baseline serum value PSA neuro-endocrine marker ) . Secondary objective include evaluation toxicity , duration response , progression-free-survival overall survival .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histological evidence prostate adenocarcinoma Metastatic disease , either measurable ( lymph node , hepatic lesion , pulmonary lesion long diameter &gt; = 1 cm spiral scan ) , non measurable ( bone metastasis ) Patients must : Have receive hormonal therapy via surgical chemical castration ( LHRH agonist ) without antiandrogens . Antiandrogen withdrawal recommend inclusion , offtreatment period least 4 week . LHRH agonist treatment must continue . Have relapse disease refractory hormonal treatment ( define testosterone level &lt; 0.5 Âµg/ml ) Have neuroendocrine progression define , whatever PSA level , : NSE and/or Chromogranin A &gt; 1.5 x upper limit normal ( ULN ) without visceral metastasis ( liver , lung , lymph node ) No increase NSE Chromogranin A , visceral metastasis ( either hepatic , pleuropulmonary , nodal ) cytological histological confirmation presence undifferentiated neuroendocrine component prostatic origin Prior treatment radiotherapy allow radiation therapy must complete least 4 week inclusion irradiate area must represent 25 % marrow reserve Prior treatment estramustine allow must stop least 4 week inclusion Age &gt; = 18 year Life expectancy &gt; = 3 month Karnofsky index &gt; = 50 % Adequate haematological function : neutrophil &gt; = 1.5 G/l , platelets &gt; = 100 G/l , haemoglobin &gt; = 8 g/dl . Use erythropoietin allow . Adequate liver function : bilirubin level within institution 's normal range , AST ALT &lt; = 1.5 ULN Adequate renal function : creatinine clearance &gt; = 40 ml/min ( Gault Cockroft method ) Signed write informed consent . Patients &gt; 1.5 x ULN increase least one neuroendocrine marker ( NSE chromogranin A ) cytological histological ( undifferentiated neuroendocrine type ) evidence visceral metastasis ( hepatic , pleuropulmonary , nodal ) History malignancy , curatively treat basal cell skin carcinoma curatively treat cancer sign recurrence within 5 year Symptomatically uncontrolled brain metastasis Interstitial radiation therapy ( use strontium samarium ) within previous 3 month Prior treatment platinum salt etoposide . Other chemotherapy regimen allow provide last dose administer &gt; = 4 week prior inclusion . Concomitant treatment anticancer drug , except corticoid LHRH agonist injection Peripheral neuropathy &gt; = 2 ( NCICTCAE ) Uncontrolled progressive thromboembolic disease Uncontrolled infection Medical history acute myocardial infection uncontrolled angina pectoris , hypertension uncontrolled arrythmia Inclusion another clinical trial Impaired followup social , geographical , familial psychological reason Any unstable disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hormone resistant prostate cancer</keyword>
	<keyword>Neuro-endocrine marker</keyword>
	<keyword>Carboplatin-Etoposide combination</keyword>
	<keyword>Neuro-endocrine differentiation</keyword>
</DOC>